转移性去势抵抗性前列腺癌患者接受二氯化镭-223治疗诱导的前列腺特异性抗原闪烁现象
本回顾性研究纳入168例接受二氯化镭-223治疗的转移性去势抵抗性前列腺癌患者,评估不同定义的前列腺特异性抗原(PSA)闪烁对生存的影响及其与18F-氟化钠PET/CT代谢参数的关系。结果显示,首周期后升高但随后降至基线以下的PSA闪烁组,其中位无进展生存期和总生存期与立即PSA下降组无显著差异,但显著优于持续PSA升高组。作者认为闪烁不一定提示对二氯化镭-223治疗无反应。
要点
- PSA闪烁(首周期后升高、随后降至基线以下)见于20例(11.9%),其中位PFS 20.8个月、OS 23.9个月。
- PSA闪烁组生存与立即PSA下降组无显著差异,但显著优于持续PSA升高组(PFS 3.1个月、OS 11.5个月,p<0.001)。
- PSA闪烁组碱性磷酸酶下降显著大于无应答者(p=0.003),ΔTLF10和ΔFTV10所示肿瘤负荷减少更明显。
核心结论
- 本报告提示,PSA闪烁不一定提示对二氯化镭-223治疗缺乏反应。
研究设计与样本
- 回顾性研究纳入168例接受二氯化镭-223治疗的转移性去势抵抗性前列腺癌患者,中位年龄69岁,中位PSA 29.7。
- 按不同PSA闪烁定义分组,采用Kaplan-Meier法估计总生存期(OS)和无进展生存期(PFS),并用log-rank检验比较。
- 分析18F-氟化钠PET/CT代谢参数,35例患者有基线和二氯化镭-223治疗期间的代谢数据。
主要发现
- 立即PSA下降见于49例(29.2%),无PSA反应见于59例(35.1%)。
- PSA闪烁(首周期后升高、随后降至基线以下)见于20例(11.9%),PSA闪烁后自峰值下降但未降至基线以下见于40例(23.8%)。
- PSA闪烁(降至基线以下)亚组中位PFS 20.8个月、中位OS 23.9个月,与立即PSA下降组无显著差异,但显著优于持续PSA升高组(PFS 3.1个月、OS 11.5个月,p<0.001)。
- PSA闪烁组碱性磷酸酶下降显著大于无应答者(p=0.003)。
- 35例有代谢18F-氟化钠PET/CT数据的患者中,PSA闪烁(降至基线以下)组较无应答者ΔTLF10和ΔFTV10所示肿瘤负荷减少更明显(p=0.005和0.001)。
关键数值与推荐
- PSA闪烁定义为首周期后升高、随后降至基线以下。
- PSA闪烁后自峰值下降但未降至基线以下为另一分组定义。
- 持续PSA升高组中位PFS 3.1个月、中位OS 11.5个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate-specific antigen (PSA) flare is a well-known phenomenon in patients with prostate cancer, but its impact during radium-223 dichloride (223RaCl2) therapy is still unclear. This radioisotope has shown to improve overall survival in metastatic castration-resistant prostate cancer (mCRPC). We sought to evaluate the impact of PSA flare on survival and its relation with metabolic parameters on 18F-labeled sodium fluoride PET/CT. METHODS: We conducted a retrospective study of 168 patients with mCRPC (median age 69; median PSA 29.7) receiving 223RaCl2. Overall survival (OS) and progression-free survival (PFS), estimated by the Kaplan-Meier method and compared using a log-rank test, were evaluated for patient groups corresponding to different definitions of PSA flare. Metabolic 18F-fluoride PET/CT data were analyzed as well. RESULTS: Immediate PSA decline was observed in 49 patients (29.2%), whereas no PSA response was observed in 59 patients (35.1%). PSA flare (defined as rise after the first cycle followed by decrease below the baseline) was observed in 20 patients (11.9%) and PSA flare followed by a decrease from peak but not below baseline was observed in 40 (23.8%). The first flare subgroup had a median PFS and OS of 20.8 and 23.9 months, respectively. These outcomes were not significantly different from patients with immediate PSA decrease, but were significantly better than in patients with persistent PSA elevation (3.1 months for PFS and 11.5 months for OS, p < 0.001). Moreover, the PSA flare group showed an alkaline phosphatase (ALP) decrease significantly greater than non-responders (p = 0.003). Metabolic 18F-fluoride PET/CT data were available in 35 patients at baseline and during 233RaCl2 therapy. The tumor burden reduction, expressed by ΔTLF10 and ΔFTV10, was more evident within PSA flare group below baseline than non-responders (p = 0.005 and 0.001, respectively). CONCLUSIONS: This report suggests that a flare does not necessarily indicate lack of response to 223RaCl2 therapy.
引用
- Castello A, Macapinlac HA, Lopci E, et al. Prostate-specific antigen flare induced by 223RaCl2 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018. PMID: 29785515. doi:10.1007/s00259-018-4051-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。